Page 7 - Evans Dellon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Sanofi - Aventis Groupe, Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis

United statesFrance generalEva schaefer jansenCorentine driancourtFelix lauscherAshleigh dixonVesna tosicNathalie phamSally bainEvans dellonPriya nanduriRegeneron pharmaceuticals incRegeneron genetics centerDupilumab development programAmerican academy of allergyTeva pharmaceutical industries ltd